Altimmune (ALT) Invested Capital (2010 - 2026)

Altimmune (ALT) has 17 years of Invested Capital data on file, last reported at $319.0 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $319.0 million, up 124.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $319.0 million (up 124.38% YoY), and the FY2025 annual result was $259.9 million, up 110.43% from the prior year.
• Invested Capital climbed to $319.0 million in Q1 2026 per ALT's latest filing, from $259.9 million in the prior quarter.
• Over five years, Invested Capital peaked at $319.0 million in Q1 2026 and troughed at $123.5 million in Q4 2024.
• A 5-year average of $184.4 million and a median of $176.4 million in 2025 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2024 and 2026: Invested Capital plunged 36.37% in 2024, then surged 124.38% in 2026.
• A 5-year view of Invested Capital shows it stood at $185.3 million in 2022, then grew by 4.75% to $194.1 million in 2023, then sank by 36.37% to $123.5 million in 2024, then soared by 110.43% to $259.9 million in 2025, then advanced by 22.74% to $319.0 million in 2026.
• Business Quant data shows ALT's Invested Capital at $319.0 million in Q1 2026, $259.9 million in Q4 2025, and $200.6 million in Q3 2025.